Table of Contents Author Guidelines Submit a Manuscript
Dermatology Research and Practice
Volume 2010, Article ID 657406, 11 pages
http://dx.doi.org/10.1155/2010/657406
Review Article

Metastatic Melanomas Express Inhibitory Low Affinity Fc Gamma Receptor and Escape Humoral Immunity

1INSERM, U872, Microenvironnement Immunitaire et Tumeurs, Equipe 13, Centre de Recherche des Cordeliers, 75006 Paris, France
2UMRS 872, Universite Pierre et Marie Curie, 75005 Paris, France
3UMRS 872, Universite Paris Descartes, 75006 Paris, France
4The Feinstein Institute for Medical Research, North-Shore Long Island Jewish Health System, Manhassett, NY 11030, USA
5Unite d'Allergologie Moleculaire et Cellulaire, Institut Pasteur, 75724 Paris, France
6Department of Immunology, National Jewish Health, University of Colorado, Denver, CO 80045, USA

Received 16 December 2009; Accepted 1 April 2010

Academic Editor: Keith Hoek

Copyright © 2010 Joel F. G. Cohen-Solal et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Q. Kaas, F. Ehrenmann, and M.-P. Lefranc, “IG, TR and IgSF, MHC and MhcSF: what do we learn from the IMGT Colliers de Perles?” Briefings in Functional Genomics and Proteomics, vol. 6, no. 4, pp. 253–264, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. T. Brümmendorf and F. G. Rathjen, “Cell adhesion molecules 1: immunoglobulin superfamily,” Protein Profile, vol. 2, no. 9, pp. 963–1108, 1995. View at Google Scholar · View at Scopus
  3. D. M. Halaby and J. P. E. Mornon, “The immunoglobulin superfamily: an insight on its tissular, species, and functional diversity,” Journal of Molecular Evolution, vol. 46, no. 4, pp. 389–400, 1998. View at Publisher · View at Google Scholar · View at Scopus
  4. W. Q. Qiu, D. de Bruin, B. H. Brownstein, R. Pearse, and J. V. Ravetch, “Organization of the human and mouse low-affinity Fc γ R genes: duplication and recombination,” Science, vol. 248, no. 4956, pp. 732–735, 1990. View at Google Scholar · View at Scopus
  5. M. Reth, “Antigen receptor tail clue,” Nature, vol. 338, no. 6214, pp. 383–384, 1989. View at Google Scholar · View at Scopus
  6. J. C. Cambier, “Antigen and Fc receptor signaling the awesome power of the immunoreceptor tyrosine-based activation motif (ITAM),” Journal of Immunology, vol. 155, no. 7, pp. 3281–3285, 1995. View at Google Scholar · View at Scopus
  7. S. Amigorena, C. Bonnerot, J. R. Drake et al., “Cytoplasmic domain heterogeneity and functions of IgG Fc receptor in B lymphocytes,” Science, vol. 256, no. 5065, pp. 1808–1812, 1992. View at Google Scholar · View at Scopus
  8. M. Daëron, S. Latour, O. Malbec et al., “The same tyrosine-based inhibition motif, in the intracytoplasmic domain of Fc γ RIIB, regulates negatively BCR-, TCR-, and FcR-dependent cell activation,” Immunity, vol. 3, no. 5, pp. 635–646, 1995. View at Google Scholar · View at Scopus
  9. J.-P. Kinet and P. Launay, “Fc α/μR: single member or first born in the family?” Nature Immunology, vol. 1, no. 5, pp. 371–372, 2000. View at Google Scholar · View at Scopus
  10. W. H. Fridman, C. Bonnerot, M. Daeron, S. Amigorena, J.-L. Teillaud, and C. Sautes, “Structural bases of Fc γ receptor functions,” Immunological Reviews, no. 125, pp. 49–76, 1992. View at Google Scholar · View at Scopus
  11. M. D. Hulett and P. M. Hogarth, “Molecular basis of Fc receptor function,” Advances in Immunology, vol. 57, pp. 1–127, 1994. View at Google Scholar · View at Scopus
  12. J. V. Ravetch and S. Bolland, “IgG Fc receptors,” Annual Review of Immunology, vol. 19, pp. 275–290, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. J. F. Cohen-Solal, L. Cassard, W.-H. Fridman, and C. Sautès-Fridman, “Fc γ receptors,” Immunology Letters, vol. 92, no. 3, pp. 199–205, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. F. Nimmerjahn and J. V. Ravetch, “Analyzing antibody-Fc-receptor interactions,” Methods in Molecular Biology, vol. 415, pp. 151–162, 2008. View at Google Scholar · View at Scopus
  15. E. M. Fournier, S. Sibéril, A. Costes et al., “Activation of human peripheral IgM+ B cells is transiently inhibited by BCR-independent aggregation of Fc gammaRIIB,” Journal of Immunology, vol. 181, no. 8, pp. 5350–5359, 2008. View at Google Scholar · View at Scopus
  16. R. N. Pearse, T. Kawabe, S. Bolland, R. Guinamard, T. Kurosaki, and J. V. Ravetch, “SHIP recruitment attenuates Fc γ RIIB-induced B cell apoptosis,” Immunity, vol. 10, no. 6, pp. 753–760, 1999. View at Publisher · View at Google Scholar · View at Scopus
  17. S.-J. Tzeng, S. Bolland, K. Inabe, T. Kurosaki, and S. K. Pierce, “The B cell inhibitory Fc receptor triggers apoptosis by a novel c-Abl family kinase-dependent pathway,” Journal of Biological Chemistry, vol. 280, no. 42, pp. 35247–35254, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. Z. Xiang, A. J. Cutler, R. J. Brownlie et al., “FcγRllb controls bone marrow plasma cell persistence and apoptosis,” Nature Immunology, vol. 8, no. 4, pp. 419–429, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. U. Sahin, Ö. Türeci, H. Schmitt et al., “Human neoplasms elicit multiple specific immune responses in the autologous host,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 25, pp. 11810–11813, 1995. View at Publisher · View at Google Scholar · View at Scopus
  20. E. Jäger, Y.-T. Chen, J. W. Drijfhout et al., “Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes,” Journal of Experimental Medicine, vol. 187, no. 2, pp. 265–270, 1998. View at Publisher · View at Google Scholar · View at Scopus
  21. D. F. Lake, W. C. Huynh, and E. M. Hersh, “Natural and induced human antibody response to cancer,” Cancer Investigation, vol. 18, no. 5, pp. 480–489, 2000. View at Google Scholar · View at Scopus
  22. G. Ragupathi, M. Meyers, S. Adluri, L. Howard, C. Musselli, and P. O. Livingston, “Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21,” International Journal of Cancer, vol. 85, no. 5, pp. 659–666, 2000. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Lutzky, A. M. Gonzalez-Angulo, and J. A. Orzano, “Antibody-based vaccines for the treatment of melanoma,” Seminars in Oncology, vol. 29, no. 5, pp. 462–470, 2002. View at Publisher · View at Google Scholar · View at Scopus
  24. H. Ehlken, D. Schadendorf, and S. Eichmüller, “Humoral immune response against melanoma antigens induced by vaccination with cytokine gene-modified autologous tumor cells,” International Journal of Cancer, vol. 108, no. 2, pp. 307–313, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. C. A. White, J. R. Berlfein, and A. J. Grillo-López, “Antibody-targeted immunotherapy for treatment of non-Hodgkin's lymphoma,” Current Pharmaceutical Biotechnology, vol. 1, no. 4, pp. 303–312, 2000. View at Google Scholar · View at Scopus
  26. P. J. Carter, “Potent antibody therapeutics by design,” Nature Reviews Immunology, vol. 6, no. 5, pp. 343–357, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. K. Akiyama, S. Ebihara, A. Yada et al., “Targeting apoptotic tumor cells to Fc γ R provides efficient and versatile vaccination against tumors by dendritic cells,” Journal of Immunology, vol. 170, no. 4, pp. 1641–1648, 2003. View at Google Scholar · View at Scopus
  28. K. Rafiq, A. Bergtold, and R. Clynes, “Immune complex-mediated antigen presentation induces tumor immunity,” Journal of Clinical Investigation, vol. 110, no. 1, pp. 71–79, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. D. O. Adams, T. Hall, Z. Steplewski, and H. Koprowski, “Tumors undergoing rejection induced by monoclonal antibodies of the IgG2a isotype contain increased numbers of macrophages activated for a distinctive form of antibody-dependent cytolysis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 81, no. 11 I, pp. 3506–3510, 1984. View at Google Scholar · View at Scopus
  30. E. Y. Denkers, C. C. Badger, J. A. Ledbetter, and I. D. Bernstein, “Influence of antibody isotype on passive serotherapy of lymphoma,” Journal of Immunology, vol. 135, no. 3, pp. 2183–2186, 1985. View at Google Scholar · View at Scopus
  31. D. G. Maloney, T. M. Liles, D. K. Czerwinski et al., “Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma,” Blood, vol. 84, no. 8, pp. 2457–2466, 1994. View at Google Scholar · View at Scopus
  32. M. J. S. Dyer, G. Hale, F. G. J. Hayhoe, and H. Waldmann, “Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype,” Blood, vol. 73, no. 6, pp. 1431–1439, 1989. View at Google Scholar · View at Scopus
  33. R. Clynes, Y. Takechi, Y. Moroi, A. Houghton, and J. V. Ravetch, “Fc receptors are required in passive and active immunity to melanoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 2, pp. 652–656, 1998. View at Publisher · View at Google Scholar · View at Scopus
  34. L. Bevaart, M. J. H. Jansen, M. J. van Vugt, J. Sjef Verbeek, J. G. J. van de Winkel, and J. H. W. Leusen, “The high-affinity IgG receptor, FcγRI, plays a central role in antibody therapy of experimental melanoma,” Cancer Research, vol. 66, no. 3, pp. 1261–1264, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. F. Nimmerjahn, P. Bruhns, K. Horiuchi, and J. V. Ravetch, “FcγRIV: a novel FcR with distinct IgG subclass specificity,” Immunity, vol. 23, no. 1, pp. 41–51, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. F. Nimmerjahn and J. V. Ravetch, “Fcγ receptors: old friends and new family members,” Immunity, vol. 24, no. 1, pp. 19–28, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. M. A. Otten, G. J. van der Bij, S. J. Verbeek et al., “Experimental antibody therapy of liver metastases reveals functional redundancy between Fc gammaRI and Fc gammaRIV,” Journal of Immunology, vol. 181, no. 10, pp. 6829–6836, 2008. View at Google Scholar · View at Scopus
  38. R. A. Clynes, T. L. Towers, L. G. Presta, and J. V. Ravetch, “Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets,” Nature Medicine, vol. 6, no. 4, pp. 443–446, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. A. B. Van Spriel, H. H. van Ojik, A. Bakker, M. J. H. Jansen, and J. G. J. van de Winkel, “Mac-1 (CD11b/CD18) is crucial for effective fc receptor-mediated immunity to melanoma,” Blood, vol. 101, no. 1, pp. 253–258, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. P. Muretto, “Immunohistochemical study of dendritic cells in foetal skin and lymph-nodes supporting the hypothesis for the neural crest origin of Langerhans cells,” Italian Journal of Anatomy and Embryology, vol. 113, no. 4, pp. 237–247, 2008. View at Google Scholar · View at Scopus
  41. P. Muretto, “The relationship of langerhans cells to melanocytes and schwann cells in mature cystic teratomas of the ovary,” International Journal of Surgical Pathology, vol. 15, no. 3, pp. 266–271, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  42. D. A. Schmitt, D. Hanau, T. Bieber et al., “Human epidermal Langerhans cells express only the 40-kilodalton Fc γ receptor (FcRII),” Journal of Immunology, vol. 144, no. 11, pp. 4284–4890, 1990. View at Google Scholar · View at Scopus
  43. C. A. Vedeler, R. Matre, E. K. Kristoffersen, and E. Ulvestad, “IgG Fc receptor heterogeneity in human peripheral nerves,” Acta Neurologica Scandinavica, vol. 84, no. 3, pp. 177–180, 1991. View at Google Scholar · View at Scopus
  44. K. Nakamura, H. Hirai, T. Torashima et al., “CD3 and immunoglobulin G Fc receptor regulate cerebellar functions,” Molecular and Cellular Biology, vol. 27, no. 14, pp. 5128–5134, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. D. D. Sedmak, D. H. Davis, U. Singh, J. G. J. van de Winkel, and C. L. Anderson, “Expression of IgG Fc receptor antigens in placenta and on endothelial cells in humans. An immunohistochemical study,” American Journal of Pathology, vol. 138, no. 1, pp. 175–181, 1991. View at Google Scholar · View at Scopus
  46. T. W. Lyden, J. M. Robinson, S. Tridandapani et al., “The Fc receptor for IgG expressed in the villus endothelium of human placenta is Fc γ RIIb2,” Journal of Immunology, vol. 166, no. 6, pp. 3882–3889, 2001. View at Google Scholar · View at Scopus
  47. V. Estienne, C. Duthoit, M. Reichert et al., “Androgen-dependent expression of FcγRIIB2 by thyrocytes from patients with autoimmune Graves' disease: a possible molecular clue for sex dependence of autoimmune disease,” FASEB Journal, vol. 16, no. 9, pp. 1087–1092, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  48. F. Milgrom, L. J. Humphrey, O. Tönder, J. Yasuda, and E. Witebsky, “Antibody-mediated hemadsorption by tumor tissues,” International Archives of Allergy and Applied Immunology, vol. 33, no. 5, pp. 478–492, 1968. View at Google Scholar · View at Scopus
  49. O. Tonder and S. Thunold, “Receptors for immunoglobulin Fc in human malignant tissues,” Scandinavian Journal of Immunology, vol. 2, no. 3, pp. 207–215, 1973. View at Google Scholar · View at Scopus
  50. I. P. Witz, “The biological significance of tumor-bound immunoglobulins,” Current Topics in Microbiology and Immunology, vol. 61, pp. 151–171, 1973. View at Google Scholar · View at Scopus
  51. H. Biran, G. M. Mavligit, and J. L. Moake, “Receptor sites for complement and for immune complexes on human nonhemopoietic tumor cells,” Cancer, vol. 44, no. 1, pp. 131–135, 1979. View at Google Scholar · View at Scopus
  52. H. W. Noltenius, “Fc and complement receptors on malignant tumor cells,” Cancer, vol. 48, no. 8, pp. 1761–1767, 1981. View at Google Scholar · View at Scopus
  53. G. R. Braslawsky, M. Yaackubowicz, A. Frensdorff, and I. P. Witz, “Receptors for immune complexes on cells within a non lymphoid murine tumor,” Journal of Immunology, vol. 116, no. 6, pp. 1571–1578, 1976. View at Google Scholar · View at Scopus
  54. J.-L. Svennevig and T. R. Andersson, “Cells bearing Fc receptors in human malignant solid tumours,” British Journal of Cancer, vol. 45, no. 2, pp. 201–208, 1982. View at Google Scholar · View at Scopus
  55. M. Ran, J.-L. Teillaud, W. H. Fridman et al., “Increased expression of Fc γ receptor in cancer patients and tumor bearing mice,” Molecular Immunology, vol. 25, no. 11, pp. 1159–1167, 1988. View at Google Scholar · View at Scopus
  56. M. Ran, B. Katz, N. Kimchi et al., “In vivo acquisition of Fc γ RII expression on polyoma virus-transformed cells derived from tumors of long latency,” Cancer Research, vol. 51, no. 2, pp. 612–618, 1991. View at Google Scholar · View at Scopus
  57. S. Szymaniec and K. James, “Studies on the Fc receptor bearing cells in a transplanted methylcholanthrene induced mouse fibrosarcoma,” British Journal of Cancer, vol. 33, no. 1, pp. 36–50, 1976. View at Google Scholar · View at Scopus
  58. G. Gorini, M. T. Ciotti, G. Starace, E. Vigneti, and G. Raschellà, “Fc gamma receptors are expressed on human neuroblastoma cell lines: lack of correlation with N-myc oncogene activity,” International Journal of Neuroscience, vol. 62, no. 3-4, pp. 287–297, 1992. View at Google Scholar · View at Scopus
  59. L. Cassard, J. F. G. Cohen-Solal, A. Galinha et al., “. Modulation of tumor growth by inhibitory Fc(gamma) receptor expressed by human melanoma cells,” Journal of Clinical Investigation, vol. 110, no. 10, pp. 1549–1557, 2002. View at Publisher · View at Google Scholar · View at Scopus
  60. L. Cassard, J. F. G. Cohen-Solal, E. M. Fournier et al., “Selective expression of inhibitory Fcγ receptor by metastatic melanoma impairs tumor susceptibility to IgG-dependent cellular response,” International Journal of Cancer, vol. 123, no. 12, pp. 2832–2839, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  61. C. A. Vedeler, E. Scarpini, S. Beretta, R. Doronzo, and R. Matre, “The ontogenesis of Fc γ receptors and complement receptors CR1 in human peripheral nerve,” Acta Neuropathologica, vol. 80, no. 1, pp. 35–40, 1990. View at Google Scholar · View at Scopus
  62. C. Neauport-Sautes, M. Daëron, J. L. Teillaud, U. Blank, and W. H. Fridman, “The occurrence, structural and functional properties of immunoglobulin Fc receptors on murine neoplastic cells,” International Reviews of Immunology, vol. 1, no. 3-4, pp. 237–271, 1986. View at Google Scholar · View at Scopus
  63. S. Tridandapani, Y. Wang, C. B. Marsh, and C. L. Anderson, “Src homology 2 domain-containing inositol polyphosphate phosphatase regulates NF-κ B-mediated gene transcription by phagocytic Fc γ Rs in human myeloid cells,” Journal of Immunology, vol. 169, no. 8, pp. 4370–4378, 2002. View at Google Scholar · View at Scopus
  64. T. Rothhammer, I. Poser, F. Soncin, F. Bataille, M. Moser, and A.-K. Bosserhoff, “Bone morphogenic proteins are overexpressed in malignant melanoma and promote cell invasion and migration,” Cancer Research, vol. 65, no. 2, pp. 448–456, 2005. View at Google Scholar · View at Scopus
  65. M. Ran, A. B. B. Langer, I. Eliassi et al., “Possibilities of interference with the immune system of tumor bearers by non-lymphoid Fc γ RII expressing tumor cells,” Immunobiology, vol. 185, no. 2–4, pp. 415–425, 1992. View at Google Scholar
  66. T. Zusman, O. Gohar, I. Eliassi et al., “The murine Fc-γ (Fc γ) receptor type II B1 is a tumorigenicity-enhancing factor in polyoma-virus-transformed 3T3 cells,” International Journal of Cancer, vol. 65, no. 2, pp. 221–229, 1996. View at Publisher · View at Google Scholar · View at Scopus
  67. T. Zusman, E. Lisansky, E. Arons et al., “Contribution of the intracellular domain of murine FC-gamma receptor type IIB1 to its tumor-enhancing potential,” International Journal of Cancer, vol. 68, no. 2, pp. 219–227, 1996. View at Publisher · View at Google Scholar · View at Scopus
  68. D.-H. Yu, C.-K. Qu, O. Henegariu, X. Lu, and G.-S. Feng, “Protein-tyrosine phosphatase Shp-2 regulates cell spreading, migration, and focal adhesion,” Journal of Biological Chemistry, vol. 273, no. 33, pp. 21125–21131, 1998. View at Publisher · View at Google Scholar · View at Scopus
  69. F.-M. Wang, H.-Q. Liu, S.-R. Liu, S.-P. Tang, L. Yang, and G.-S. Feng, “SHP-2 promoting migration and metastasis of MCF-7 with loss of E-cadherin, dephosphorylation of FAK and secretion of MMP-9 induced by IL-1β in vivo and in vitro,” Breast Cancer Research and Treatment, vol. 89, no. 1, pp. 5–14, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  70. K. Yo, S. Iwata, Y. Hashizume et al., “SHP-2 inhibits tyrosine phosphorylation of Cas-L and regulates cell migration,” Biochemical and Biophysical Research Communications, vol. 382, no. 1, pp. 210–214, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  71. S. Vijayasaradhi, B. Bouchard, and A. N. Houghton, “The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product,” Journal of Experimental Medicine, vol. 171, no. 4, pp. 1375–1380, 1990. View at Google Scholar · View at Scopus
  72. I. Hara, Y. Takechi, and A. N. Houghton, “Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein,” Journal of Experimental Medicine, vol. 182, no. 5, pp. 1609–1614, 1995. View at Publisher · View at Google Scholar · View at Scopus
  73. S. Shibahara, S. Okinaga, Y. Tomita et al., “A point mutation in the tyrosinase gene of BALB/c albino mouse causing the cysteine-serine substitution at position 85,” European Journal of Biochemistry, vol. 189, no. 2, pp. 455–461, 1990. View at Google Scholar · View at Scopus
  74. Y. Takechi, I. Hara, C. Naftzger, Y. Xu, and A. N. Houghton, “A melanosomal membrane protein is a cell surface target for melanoma therapy,” Clinical Cancer Research, vol. 2, no. 11, pp. 1837–1842, 1996. View at Google Scholar · View at Scopus
  75. J. Trcka, Y. Moroi, R. A. Clynes et al., “Redundant and alternative roles for activating Fc receptors and complement in an antibody-dependent model of autoimmune vitiligo,” Immunity, vol. 16, no. 6, pp. 861–868, 2002. View at Publisher · View at Google Scholar · View at Scopus
  76. A. B. van Spriel, J. H. W. Leusen, M. van Egmond et al., “Mac-1 (CD11b/CD18) is essential for Fc receptor-mediated neutrophil cytotoxicity and immunologic synapse formation,” Blood, vol. 97, no. 8, pp. 2478–2486, 2001. View at Publisher · View at Google Scholar · View at Scopus
  77. J. Thurin, M. Thurin, and Y. Kimoto, “Monoclonal antibody-defined correlations in melanoma between levels of G(D2) and G(D3) antigens and antibody-mediated cytotoxicity,” Cancer Research, vol. 47, no. 5, pp. 1229–1233, 1987. View at Google Scholar
  78. N. Gross, D. Beck, J. Portoukalian, S. Favre, and S. Carrel, “New anti-GD2 monoclonal antibodies produced from gamma-interferon-treated neuroblastoma cells,” International Journal of Cancer, vol. 43, no. 4, pp. 665–671, 1989. View at Google Scholar · View at Scopus
  79. N. Saito, R. K. Yu, and N. K. V. Cheung, “Ganglioside GD2 specificity of monoclonal antibodies to human neuroblastoma cell,” Biochemical and Biophysical Research Communications, vol. 127, no. 1, pp. 1–7, 1985. View at Google Scholar · View at Scopus
  80. R. N. Pearse, T. Kawabe, S. Bolland, R. Guinamard, T. Kurosaki, and J. V. Ravetch, “SHIP recruitment attenuates Fc γ RIIB-induced B cell apoptosis,” Immunity, vol. 10, no. 6, pp. 753–760, 1999. View at Publisher · View at Google Scholar · View at Scopus
  81. D. A. Litvak, R. K. Gupta, R. Yee, L. A. Wanek, W. Ye, and D. L. Morton, “Endogenous immune response to early- and intermediate-stage melanoma is correlated with outcomes and is independent of locoregional relapse and standard prognostic factors,” Journal of the American College of Surgeons, vol. 198, no. 1, pp. 27–35, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  82. R. K. Gupta, A. M. Leitch, and D. L. Morton, “Nature of antigens and antibodies in immune complexes isolated by staphylococcal protein A from plasma of melanoma patients,” Cancer Immunology, Immunotherapy, vol. 16, no. 1, pp. 40–47, 1983. View at Google Scholar · View at Scopus
  83. E. C. Hsueh, R. K. Gupta, K. Qi, and D. L. Morton, “Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine,” Journal of Clinical Oncology, vol. 16, no. 9, pp. 2913–2920, 1998. View at Google Scholar · View at Scopus
  84. W. R. Strohl, “Optimization of Fc-mediated effector functions of monoclonal antibodies,” Current Opinion in Biotechnology, vol. 20, no. 6, pp. 685–691, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  85. S. Sibéril, C.-A. Dutertre, W.-H. Fridman, and J.-L. Teillaud, “FcγR: the key to optimize therapeutic antibodies?” Critical Reviews in Oncology/Hematology, vol. 62, no. 1, pp. 26–33, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  86. S. Sibéril, C.-A. Dutertre, C. Boix et al., “Molecular aspects of human FcγR interactions with IgG: functional and therapeutic consequences,” Immunology Letters, vol. 106, no. 2, pp. 111–118, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  87. C. De Romeuf, C.-A. Dutertre, M. Le Garff-Tavernier et al., “Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcγRIIIA/CD16,” British Journal of Haematology, vol. 140, no. 6, pp. 635–643, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  88. M.-C. Veri, S. Gorlatov, H. Li et al., “Monoclonal antibodies capable of discriminating the human inhibitory Fcγ-receptor IIB (CD32B) from the activating Fcγ-receptor IIA (CD32A): biochemical, biological and functional characterization,” Immunology, vol. 121, no. 3, pp. 392–404, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  89. C. T. Rankin, M.-C. Veri, S. Gorlatov et al., “CD32B, the human inhibitory Fc-γ receptor IIB, as a target for monoclonal antibody therapy of B-cell lymphoma,” Blood, vol. 108, no. 7, pp. 2384–2391, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  90. S. Shah, A. A. Divekar, S. P. Hilchey et al., “Increased rejection of primary tumors in mice lacking B cells: inhibition of anti-tumor CTL and T1 cytokine responses by B cells,” International Journal of Cancer, vol. 117, no. 4, pp. 574–586, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  91. D. J. Dilillo, K. Yanaba, and T. F. Tedder, “B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice,” Journal of Immunology, vol. 184, pp. 4006–4016, 2010. View at Google Scholar
  92. M. E. Polak, N. J. Borthwick, F. G. Gabriel et al., “Mechanisms of local immunosuppression in cutaneous melanoma,” British Journal of Cancer, vol. 96, no. 12, pp. 1879–1887, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  93. S. Tridandapani, R. Wardrop, C. P. Baran et al., “TGF-β1 supresses myeloid Fc γ receptor function by regulating the expression and function of the common γ-subunit,” Journal of Immunology, vol. 170, no. 9, pp. 4572–4577, 2003. View at Google Scholar · View at Scopus
  94. T. Joshi, L. P. Ganesan, X. Cao, and S. Tridandapani, “Molecular analysis of expression and function of hFcγRIIbl and b2 isoforms in myeloid cells,” Molecular Immunology, vol. 43, no. 7, pp. 839–850, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  95. R. Trotta, J. D. Col, J. Yu et al., “TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells,” Journal of Immunology, vol. 181, no. 6, pp. 3784–3792, 2008. View at Google Scholar · View at Scopus